Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation

被引：0

作者：

Cho, B. C. ^{[1
]}

Shen, Y. ^{[2
]}

Li, Z. ^{[3
]}

Lu, S. ^{[3
]}

Lee, M. A. ^{[4
]}

Song, Z. ^{[5
]}

Park, J. J. W. ^{[6
]}

Lim, S. M. ^{[1
]}

Zhao, J. ^{[7
]}

Richardson, G. ^{[8
]}

Zhang, Y. ^{[9
]}

Zhang, J. ^{[2
,10
]}

Liu, A. ^{[11
]}

Chen, C. ^{[2
]}

Liu, Y. ^{[2
]}

Rui, H. ^{[2
]}

Chen, J. Q. ^{[2
]}

Wang, A. H. ^{[2
]}

Zhang, J. ^{[2
,10
]}

Mok, T. S. K. ^{[12
]}

机构：

[1] Yonsei Univ, ABMRC, Med Oncol Dept 501, Seoul, South Korea

[2] D3 Bio Wuxi Co Ltd, Clin Dev Dept, Shanghai, Peoples R China

[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China

[4] Catholic Univ Korea, Seoul St Marys Hosp, Internal Med Dept, Catholic Med Ctr, Seoul, South Korea

[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Clin Trials Dept, Hangzhou, Peoples R China

[6] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept Level 1, Sydney, NSW, Australia

[7] Beijing Canc Hosp, Dept Oncol, Beijing, Peoples R China

[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Szalmuk Family Dept Med Oncol, Malvern, Vic, Australia

[9] Harbin Med Univ, Canc Hosp, Gastroenterol Dept, Harbin, Peoples R China

[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Oncol Dept, Shanghai, Peoples R China

[11] Nanchang Univ, Affiliated Hosp 2, Oncol Dept, Nanchang, Jiangxi, Peoples R China

[12] Prince Wales Hosp, Clin Oncol Dept, Li Ka Shing Specialist Clin, Hong Kong, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.673

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

640P

引用

页码：S1642 / S1643

页数：2

共 50 条

[1] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
Cho, B. C.
Lu, S.
Lee, M. A.
Song, Z.
Park, J. J. W.
Lim, S. M.
Li, Z.
Zhao, J.
Richardson, G.
Zhang, Y.
Zhang, J.
Liu, A.
Chen, C.
Wang, J.
Chen, J.
Wang, A.
Zhang, J.
Chen, Z. G.
Mok, T. S. K.
Johnson, M. L.
ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
[2] Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
Wang, Judy
Martin-Romano, Patricia
Cassier, Philippe
Johnson, Melissa
Haura, Eric
Lenox, Laurie
Guo, Yue
Bandyopadhyay, Nibedita
Russell, Michael
Shearin, Elizabeth
Lauring, Josh
Dahan, Laetitia
ONCOLOGIST, 2022, 27 (07): : 536 - +
[3] D3S-001, a highly potent, selective, and differentiated covalent inhibitor of KRAS G12C: Human dose prediction and first-in-human (FIH) trial design.
Lu, Jingtao
Zhang, Jing
Zheng, Zhiqiang
Chen, Cheng
Wang, Jia
Chen, Janet
Lu, Jiang
Rui, Haopeng
Wang, Allison
Chen, Zhi Jian
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
Zhou, C.
Li, W.
Song, Z.
Zhang, Y.
Zhang, Y.
Huang, D.
Yang, Z.
Zhou, M.
Mao, R.
Huang, C.
Li, X.
Wang, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273
[5] A phase I/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors.
Li, Jian
Zhao, Jun
Cao, Baoshan
Fang, Jian
Li, Xiaoyan
Wang, Mengzhao
Ba, Yi
Li, Xingya
Li, Zhihua
Liu, Zhe
Wang, Yongsheng
Cheng, Ying
Bai, Chunmei
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress).
Ammakkanavar, Natraj Reddy
Call, Justin
Shimizu, Toshio
Kuboki, Yasutoshi
Liu, Shiyao
Willard, Melinda D.
Axelson, Michael
Heist, Rebecca S.
Patnaik, Amita
CANCER RESEARCH, 2022, 82 (12)
[7] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
Cho, Byoung Chul
Lu, Shun
Lee, Myung Ah
Song, Zhengbo
Park, John
Lim, Sun Min
Li, Ziming
Zhao, Jun
Richardson, Gary
Zhang, Yanqiao
Zhang, Jun
Liu, Anwen
Chen, Cheng
Wang, Jia
Lu, Jingtao
Rui, Haopeng
Chen, Qian
Wang, Hui
Zhang, Jing
Chen, Zhi Jian
Mok, Tony
CANCER RESEARCH, 2024, 84 (07)
[8] Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
Zhou, Qing
Yang, Nong
Zhao, Mingfang
Huang, Dingzhi
Zhao, Jun
Yu, Yan
Yuan, Ying
Sun, Longhua
Dong, Xiaorong
Zhang, Tongmei
Chu, Qian
Li, Xingya
Meng, Xiangjiao
Wang, Huijuan
Wang, Xiang
Wu, Dongde
Hu, Sheng
Shan, Jinlu
Liu, Lian
Sun, Meili
Zhang, Zhiye
Zhu, Haibo
Huang, Jingjing
Huang, Mengna
Cheng, Lingge
Zhang, Sujie
Zhou, Hui
Wu, Yi-Long
EUROPEAN JOURNAL OF CANCER, 2024, 212
[9] A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
Murciano-Goroff, Yonina R.
Heist, Rebecca S.
Kuboki, Yasutoshi
Koyama, Takafumi
Ammakkanavar, Natraj Reddy
Hollebecque, Antoine
Patnaik, Amita
Shimizu, Toshio
Spira, Alexander I.
Nagasaka, Misako
Han, Ji-Youn
Iams, Wade Thomas
Deming, Dustin
Call, Justin
Cassier, Philippe
Han, Sae-Won
Chu, Quincy Siu-Chung
Cosman, Rasha
Durm, Gregory
Burns, Timothy
Willard, Melinda D.
Liu, Shiyao
Callies, Sophie
Balar, Arjun V.
Sabari, Joshua K.
CANCER RESEARCH, 2023, 83 (08)
[10] First-in-human study of ZG19018, targeting KRAS G12C, as monotherapy in patients with advanced solid tumors.
Liu, Rongrui
Qu, Xiujuan
Yang, Nong
Chai, Xiaoli
Xu, Jianming
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →